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Allergic Aspergillus sinusitis and its association 
with allergic bronchopulmonary aspergillosis
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Allergic Aspergillus sinusitis (AAS) is a three decade old clinicopathologic entity in which mucoid impaction akin to that of allergic 
bronchopulmonary aspergillosis (ABPA) occurs in the paranasal sinuses. Features such as radiographic evidence of pansinusitis, 
passage of nasal plugs and recurrent nasal polyposis in patients with an atopic background is suggestive of AAS. Histopathlogic 
confirmation from the inspissated mucus is a sine qua non for the diagnosis. Heterogeneous densities on computed tomography 
of the paranasal sinuses are caused by the ‘allergic mucin’ in the sinuses. Many patients give a history of having undergone multiple 
surgical procedures for symptomatic relief. The current approach to treatment appears to include an initial surgical debridement 
followed by postoperative oral corticosteroids for long durations. Although both ABPA and AAS are classified as Aspergillus-related 
hypersensitivity respiratory disorders, their co-occurrence appears to be an infrequently recognised phenomenon. This could perhaps 
be attributed to the fact that these two diseases are often treated by two different specialties. A high index of suspicion is required 
to establish the diagnoses of ABPA and AAS. All patients with asthma and/or rhinosinusitis along with sensitisation to Aspergillus 
antigens are at an increased risk of developing ABPA and/or AAS. ABPA must be excluded in all patients with AAS and vice versa. Early 
diagnosis and initiation of appropriate therapy could plausibly alter the course of the disease processes and prevent the possible 
development of long term sequelae. 
Key words: Allergic Aspergillus sinusitis; Allergic bronchopulmonary aspergillosis; Allergic fungal sinusitis; Aspergillus; Asthma; 
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INTRODUCTION
Aspergillus, a genus of spore-forming ubiquitous fungi, 
affects both the upper and the lower respiratory tracts [1, 2] 
and has protean manifestations (Table 1). The clinical spectrum 
of hypersensitivity manifestations in the respiratory tract 
includes Aspergillus induced asthma, allergic bronchopulmonary 
aspergillosis (ABPA) and allergic Aspergillus sinusitis (AAS). Allergic 
bronchopulmonary aspergillosis, predominantly a disease of 
the asthmatics, is well established worldwide for nearly six 
decades with reports from around the globe [3], while AAS 
is comparatively a more recently identified entity that is now 
Correspondence: Ashok Shah
Department of Respiratory Medicine, Vallabhbhai Patel chest 
Institute, University of Delhi, Delhi 110 007, P.O. Box 2101, India
Tel: +91-11-2543-3783
Fax: +91-11-2766-6549
E-mail: ashokshah99@yahoo.com
Received: September 5, 2011
Accepted: September 21, 2011
†current affiliation:  Department of Respiratory Medicine, 
Mata chanan Devi Hospital, New Delhi, India
This is an Open Access article distributed under the terms of the creative 
commons Attribution. Non-commercial License (http://creativecommons.
org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is 
properly cited.
copyright © 2011. Asia Pacific Association of Allergy, Asthma and clinical Immunology. 
http://apallergy.orgapallergy.org
AAS and its association with ABPA
http://dx.doi.org/10.5415/apallergy.2011.1.3.130 131
known for the last 30 years. We present a brief review on AAS and 
its association with ABPA.
Historical perspective
Hinson and colleagues [4] were the first to recognise ABPA, a 
potentially destructive lung disease, in England in 1952. Almost 
three decades later, in 1981, Millar and colleagues [5], also from 
England, presented five patients with chronic sinusitis, all of whom 
had pathologic resemblance to the mucoid impaction of ABPA. 
They stated this as the first description of allergic aspergillosis 
of the paranasal sinuses. In 1983, Katzenstein and coworkers 
[6] retrospectively reviewed 119 surgically obtained specimens 
from the paranasal sinuses and found that seven patients had 
pathologic findings characteristic of the mucoid impaction of 
ABPA. These investigators coined the term ‘allergic mucin’ to 
describe the nasal material comprising cellular debris, eosinophils, 
Charcot-Leyden crystals and scattered fungal hyphae. The authors 
designated this newly recognised clinicopathologic disease as 
‘allergic Aspergillus sinusitis’.
Diagnostic criteria
Once resemblance to ABPA was observed, a set of criteria was 
enunciated for the diagnosis of AAS [7, 8]. While radiologic and 
histopathologic features are key components, demonstration 
of fungal elements/culture obtained from the sinus material 
is the mainstay for the diagnosis (Table 2). Diabetics, 
immunocompromised subjects and patients with invasive fungal 
disease are excluded from the diagnosis. Other features, akin 
to those in ABPA, support the diagnosis of AAS. These include 
peripheral blood eosinophilia, cutaneous hypersensitivity to 
Aspergillus antigens, elevated total IgE levels, Aspergillus-specific 
IgE and IgG antibodies, and precipitating antibodies to Aspergillus 
antigens [9]. We have elicited type-I hypersensitivity by skin 
testing in all our patients with AAS [8]. This was complemented 
by elevated total IgE levels in all patients and the presence of 
Aspergillus-specific IgE antibodies in most of the patients.
Allergic fungal sinustis
Fungi other than Aspergillus may also cause allergic sinusitis and 
hence a comprehensive term allergic fungal sinusitis (AFS) was 
introduced [10]. A retrospective case review [11] of 67 consecutive 
patients with AFS from the United States, all of whom met the 
histopathologic criteria for the diagnosis, showed that the mould 
Bipolaris spicifera was cultured at sinus surgery in more than two-
thirds of the patients. This was followed by Aspergillus, which was 
seen in 9%. Exserohilum, Alternaria and Curvularia were grown in 
3% each while Torula was isolated in 2% of the patients. The sinus 
material was sterile in 13%. 
Prevalence in the Asia-Pacific region
With the availability of easier diagnostic surgeries and improved 
fungal culture techniques, AFS, including AAS, has now been 
widely recognised.  In the Asia-Pacific region, cases have been 
described from Australia [10], India [8, 12-14], Thailand [15], 
Table 1. Aspergillus-related respiratory disorders [1, 2]
I. Upper respiratory tract (sinus) involvement
1. Allergic: Allergic Aspergillus sinusitis
2. Saprophytic: Fungal ball
3. Invasive:  (i) Acute fulminant invasive sinusitis
  (ii) Chronic invasive sinusitis
  (iii) Granulomatous invasive sinusitis
II. Lower respiratory tract (pulmonary) involvement
1. Allergic:  (i) IgE mediated asthma
  (ii) Allergic bronchopulmonary aspergillosis
  (iii) Hypersensitivity pneumonitis
2. Saprophytic: Aspergilloma
3. Invasive:  (i) Invasive disseminated aspergillosis
  (ii) Chronic necrotising pneumonia
Table 2. Diagnostic criteria for allergic Aspergillus sinusitis [6, 7]
1. Sinusitis of one or more paranasal sinus on x-ray film
2.   Necrosed amorphous tissue along with oedematous polyps              
infilterated with eosinophils on histopathological evaluation of       
material from the sinus
3.   Demonstration of fungal elements in nasal discharge or in material 
obtained at the time of surgery by stain or culture
4.   Absence of diabetes, previous or subsequent immunodeficiency   
disease, and treatment with immuno-suppressive drugs
5.   Absence of invasive fungal disease at the time of diagnosis or          
subsequently
Other features [8]
1. Peripheral blood eosinophilia
2. Type I / type III cutaneous hypersensitivity to Aspergillus 
3. Precipitating antibodies to Aspergillus antigens
4. Elevated total as well as Aspergillus-specific IgE levels 
5. Characteristic computed tomography appearancesapallergy.org
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Malaysia [16] and Saudi Arabia [17]. We reported the first patient 
of AAS from India [12], and also described the first instance of 
concomitant occurrence of ABPA and AAS from Asia [18].  
Pathophysiology
This allergic sinus disorder of fungal origin is characterised by 
mucoid impaction in the paranasal sinuses, which is akin to that 
of ABPA. This too occurs in atopic individuals and, as in ABPA, 
it is likely that release of antigenic material from the fungi sets 
into motion a chain of immunologic reactions culminating in 
the development of AAS. We have earlier shown that a fourth of 
the patients with perennial rhinitis had positive skin reactivity to 
Aspergillus antigens [19]. Recently this was further confirmed by us 
in 131 patients with allergic rhinitis where type-I hypersensitivity 
to Aspergillus was demonstrated in 24.4% of the patients [20]. Two 
of these 131 subjects were diagnosed as AAS. Since rhinitis is an 
important predisposing factor for sinusitis, it appears that these 
patients may be at a greater risk for developing AAS. It has been 
suggested that 5 to 10% of patients with chronic rhinosinusitis 
go on to develop AFS [13, 21-23]. Human leukocyte antigen gene 
association, particularly with major histocompatibility class II 
regions, were observed in two-thirds of 44 patients with AFS from 
the United States [24]. This association has also been found in 
ABPA, a disease with similar immunopathologic mechanisms [25].
Eosinophilic mucin rhinosinusitis
In the series of 119 patients studied by Katzenstein et al. [6], 
there were another two patients who had similar histopathologic 
findings of the characteristic eosinophilic mucin plugs as seen in 
AAS but Aspergillus could not be cultured from the sinus material. 
When more reports of patients with allergic mucin without fungal 
elements were published [26-29], these were termed as having 
‘eosinophilic mucin rhinosinusitis’ (EMRS) rather than AFS. It was 
retrospectively observed that patients with EMRS, when compared 
to those with AFS, had a higher incidence of aspirin sensitive 
asthma and were older in age at presentation [29]. In addition, a 
significantly greater number were asthmatics. 
In order to differentiate such patients, Pant et al. [30] studied 
the demographic, clinical and immunologic characteristics of 
patients who were divided into four different subgroups based on 
the presence/absence of fungi in the eosinophilic mucin and the 
presence/absence of type-I hypersensitivity to fungi. Although the 
patients did not differ significantly among each other, those with 
IgE-mediated fungal allergy were almost a decade younger than 
the nonallergic patients. However, as a single group, these patients 
had more severe sinus disease when compared to those with 
chronic rhinosinusitis without eosinophilic mucin. 
Clinical features
Patients with AFS belong to a fairly younger age group, which, 
given an atopic background, is not surprising. In the retrospective 
case review [11] of 67 patients, the mean age was 33.3 years with 
a female preponderance (58%). The presentation is generally 
insidious with a history of rhinorrhoea, sneezing, nasal blockage, 
and passage of nasal plugs. History of asthma may also be elicited, 
and some of these may also complain of passage of golden 
brown sputum plugs. On physical examination, nasal polyps and 
crusts can be found which cause gradual obstruction of the ostia 
leading to accumulation of allergic mucin in the closed spaces of 
the sinuses. The expanding mass may gradually cause distortion 
of facial features, which may not be easily noticed. It can erode 
into the sinus walls to extend into the adjacent spaces such as the 
orbit, causing proptosis, and sometimes even loss of vision [31, 32]. 
A history of previous surgeries for recurrent sinusitis is also evident. 
Superimposed acute bacterial infection may lead to pain [33]. 
Radiological features
Plain roentgenograms of the paranasal sinuses
The demonstration of sinusitis on plain sinus roentgenograms 
in one or more paranasal sinuses is one of the diagnostic criteria 
for AAS [7, 8, 12]. Haziness or clouding of the sinus is the most 
common feature. More often than not, more than one sinus is 
opacified. This is in contrast to a fungal ball where almost always 
a single sinus is affected. Bilateral involvement was observed in 
up to 83% of cases reported [8, 34]. Furthermore, Waxman and 
colleagues [34] state, “when sequential time related studies were 
performed, progressive involvement of multiple sinuses was the 
rule.”
Other manifestations include mucosal thickening and varying 
degrees of bony sclerosis and/or destruction. However, these 
findings are non-specific as they may also be seen in chronic and/
or infective sinusitis or malignancies of the paranasal sinuses. 
Currently, computed tomography (CT) has emerged as the 
imaging modality of choice.
Computed tomography
A more reliable and accurate radiological diagnosis can be 
made with the help of CT of the paranasal sinuses (CT-PNS). The apallergy.org
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characteristic feature is the occurrence of heterogeneous densities, 
signifying opacification of the sinuses; with serpiginous areas 
of increased attenuation on non-contrast scans [35, 36]. These 
hyperdense areas (Fig. 1) are due to the presence of ‘allergic mucin’. 
The serpiginous pattern of the central area of high attenuation has 
also been described as ‘star-filled sky’ or ‘ground glass’ patterns 
[37]. Presence of ferromagnetic elements (iron and manganese) 
that are produced by the fungi is said to be responsible for the 
heterogeneous densities [35].  
The extent of disease is better visualised on CT-PNS. In a study of 
44 patients with AFS [26], CT scans showed involvement of three 
or more sinuses in all patients. Both unilateral [35, 38] and bilateral 
[8, 34, 39] predominance of the disease was noticed in different 
series. Mukherji et al. [36] retrospectively reviewed CT scans, along 
with surgical and histologic reports, in 45 patients with AFS and 
found an almost equal preponderence of unilateral (49%) and 
bilateral involvement (51%). All 45 patients had increased intrasinus 
attenuation with mucosal thickening on non-contrast scans. The 
ethmoid sinus complex was most frequently involved (96%), 
followed by the maxillary (93%), frontal (71%) and sphenoid (67%) 
sinuses. While complete opacification of at least one sinus was 
seen in all but one (98%) patient, multiple sinus involvement was 
noted in 96%. The CT-PNS in most of these patients demonstrated 
expansion of the opacified sinus (98%), remodeling of the bony 
sinus walls (95%) and erosion of a sinus wall (93%). A fifth of the 
patients also had evidence of involvement of adjacent soft tissue 
structures.  
The exact mechanism of the limited bony destruction, which 
has been noted in up to 80% of patients with AFS, is not clear [27, 
35, 40]. This is either due to pressure necrosis causing reabsorption 
of the bone or bone destroying enzymes produced by the fungus. 
Inflammatory mediators such as major basic protein produced by 
the allergic response could also be responsible [41, 42]. This is in 
contrast to invasive fungal aspergillosis wherein bone destruction 
is frankly evident [2].  
Prior to definitive surgery, it is important to determine 
whether there is any intracranial involvement or not [43-45]. In 
a retrospective review of 25 patients with AFS [44], extensive 
erosion of the skull base with intracranial extension of the 
disease was seen in four patients. However, histologic evidence 
of tissue invasion was absent in all 25 patients. Leakage of sinus 
contents into the orbit may also occur, and this is more clearly 
delineated on CT scanning [31, 45, 46].  A case of pansinusitis with 
orbital involvement associated with an allergic response to the 
fungus Curvularia lunata has been described [31].  An analysis 
of 21 patients with AFS revealed intracranial extension in eight 
and erosion of the lamina papyracea in six, with four of them 
having both intracranial and intraorbital involvement [45]. Orbital 
involvement may perhaps be more common in children due to the 
presence of incompletely opacified cartilaginous sinus walls [47].
Computed tomography also helps in distinguishing AFS from 
other forms of fungal sinusitis, which include acute (fulminant) 
invasive fungal sinusitis, chronic and/or indolent fungal sinusitis 
and fungal balls in the sinuses [2, 48, 49]. Aggressive bone erosion 
with extension of disease into the adjacent soft tissues, viz. dura 
mater and orbit, is a feature of acute invasive fungal sinusitis. 
Unlike in the allergic form of the disease, sinus expansion and sinus 
wall modeling is uncommon in acute invasive fungal sinusitis.   
Sometimes, a patient may present during the early stages of 
invasive fungal sinusitis well before bony erosion and tissue 
necrosis are evident on CT, which cannot be differentiated from 
noninvasive sinusitis by CT alone [50]. 
Chronic disease of the sinuses with desiccated secretions within 
mucocoeles and polyps often result in thickening and sclerosis 
of the adjacent sinus walls, while the presence of expansion 
and thinning of the sinus walls is suggestive of AFS [36]. Fungal 
balls appear as focal round areas of increased attenuation that 
Fig. 1. Computed tomography of the paranasal sinuses showing hyper-
dense lesions in the ethmoid and maxillary sinuses, suggestive of inspis-
sated secretions. apallergy.org
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are usually centered within a diseased maxillary sinus. This may 
sometimes be difficult to differentiate from AFS but the increased 
attenuation of the saprophytic colonisation in the fungal ball is 
more homogeneous than that of the allergic disease process. 
Magnetic resonance imaging
Although not the primary diagnostic procedure, magnetic 
resonance imaging (MRI) is more sensitive than CT in differentiating 
various forms of invasive and noninvasive fungal diseases of the 
paranasal sinuses [51]. On MRI, AFS is characterised by areas of 
decreased T1 weighted signal intensities [52]. These correspond to 
the hyperattenuated lesions seen on CT. On T1 weighted images, 
high signal intensity, representing inflammation, is also seen along 
the periphery of the affected sinuses. 
A central area of signal void and a narrow peripheral rim of 
increased intensity, due to the inflamed mucosa of the sinuses 
involved, is visualised on T2 weighted images. The hypodense 
regions are due to the presence of ferromagnetic elements within 
the fungal concretions [42, 51, 52]. It has also been postulated that 
the low intensity on T1 and T2 weighted images could be due 
to the high protein and low water concentration of the ‘allergic 
mucin’, while the high water content within the surrounding 
oedematous mucosa may be responsible for increased attenuation 
[45].
MRI also provides information about areas of critical importance, 
which include the cavernous sinuses and the brain. Furthermore, 
AFS can also be differentiated from other mycotic diseases of 
the paranasal sinuses. Although fungal balls of the sinuses cast a 
similar appearance of low intensity on T1 weighted images and 
signal voids on T2 weighted images, peripheral hyperintense areas 
are absent. Malignancies appear as moderately hyperintense areas 
while bacterial infections are even more hyperintense [52].  
 
The concomitant occurrence of ABPA and AAS  
The clinical categories of Aspergillus-related respiratory disorders 
seem to remain mutually exclusive. Tenacious secretions within 
the bronchi of some patients, usually asthmatics, provide a 
hospitable environment for the growth of fungi. The subsequent 
release of antigenic fungal material sets into motion a host of 
immunological reactions culminating in pulmonary damage [53]. 
Usually the disease process manifests as a type I (IgE mediated) 
hypersensitivity response, but type III (IgG mediated immune 
complexes) and type IV (cell mediated) reactions have also been 
noted. Tissue invasion, however, does not occur [54]. A similar 
syndrome can also be caused by fungi other than Aspergillus, 
which is collectively classified as allergic bronchopulmonary 
mycosis (ABPM) [55].
In spite of similar histopathological features between the 
allergic mucin of AAS and the mucous plugs of ABPA, concomitant 
occurrence of ABPA and AAS has not often been reported. 
However, our analysis of 95 patients with ABPA suggests that AAS 
may not be all that uncommon in patients with ABPA [8]. In 1976, 
Safirstein [56] reported a patient with ABPA who gave a history of 
passage of hard nasal plugs and had evidence of upper airways 
obstruction. This, in retrospect, could quite likely be a case of 
concomitant ABPA and AAS. Till date, 22 such patients have been 
published [8, 18, 57-66], 11 of whom were documented by us [8, 
18, 59, 60, 62, 66]. Four of these subjects had associated familial 
occurrence [18, 66]. These included some unique presentations 
such as associated familial occurrence of ABPA [18], middle 
lobe syndrome [59], collapsed lung with pleural effusion and 
prior operated aspergilloma [60] and a case where coexisting 
aspergilloma was also detected [62]. 
In our review of 95 patients with ABPA, 22 had radiological 
evidence of sinusitis [8]. Nine of these patients consented to 
undergo the surgical procedures required for procuring sinus 
material for histopathologic examination. Seven patients were 
confirmed as having concomitant AAS. Nasal symptoms preceded 
chest symptoms in two patients, vice versa in one and occurred 
simultaneously in four. In the remaining 13 patients the possibility 
of AAS could not be ruled out as they refused to undergo the 
invasive procedures needed to establish the diagnosis. Since 
then, the availability of minimally invasive methods has helped in 
establishing the diagnosis more easily.
To highlight the coexistence of ABPM and AFS, Venarske and 
deShazo [61], in 2002, coined the term ‘sinobronchial allergic 
mycosis’ (the SAM syndrome) to describe the expression of fungal 
hypersensitivity in both upper and lower airways. This was on the 
basis of five patients, three of whom were earlier reported by us 
for their rare presentations [18, 59, 60]. The authors further state 
in the addendum that four other cases of concomitant ABPA and 
AAS reported by us [8] also fulfill the criteria for SAM syndrome 
enunciated by them. Very recently, we retrospectively reviewed 
the records of 164 patients with ABPA diagnosed over a period of 
22 years, and found familial occurrence in four pairs. Concomitant 
AAS was present in one patient each in three of these four pairs 
[66]. 
The co-occurrence of both these diseases is yet to receive the apallergy.org
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recognition it deserves. In the Mayo Clinic series of 44 patients 
with AFS [27], there was no mention of concomitant ABPA. In 
another series of 67 consecutive cases of AFS predominantly 
caused by Bipolaris spicifera, concomitant AFS and ABPM were seen 
in only two patients [11]. Both these patients had been previously 
diagnosed with ABPM after undergoing partial lobectomy. A 
study on 126 patients of ABPA [67] from India does not mention 
any patient with nasal symptoms, or any attempt to diagnose 
concomitant AAS. Recently, a study on 20 children with fungal 
sinusitis [68] identified 11 of them with asthma, but these were not 
investigated further for the presence of ABPA. 
Treatment
A standardised protocol for the treatment of AFS has not yet 
evolved. Till date, no prospective randomised controlled studies 
are available. A combined approach with surgical debridement 
along with oral corticosteroids would most probably be required 
to manage the ongoing allergic inflammation [8, 69]. Surgery 
alone has seldom proved to be curative, and more often than not 
patients have had to undergo repeat procedures as the recurrence 
rate is high. However, during surgery, patients benefit from 
improved drainage and aeration to the sinus mucosa. Removal of 
the inspissated allergic mucin and resection of the hypertrophic 
sinus mucosa also helps in reducing fungal load. 
Based on the immuno-pathological anology of AAS with ABPA, 
treatment recommendations for the former have been formulated 
on existing guidelines for the latter. Oral prednisolone, given for 
long durations, helps not only in improving the symptomatology 
but also in prolonging recurrence after sinus surgery [70]. Addition 
of oral corticosteroids postoperatively currently remains the best 
bet for patients with AFS. We have assessed the feasibility of a bi-
weekly regimen of oral prednisolone in 26 patients with ABPA, 
two of whom had concurrent AAS as well. We found that this 
regimen was as effective as the conventional alternate day oral 
prednisolone therapy in the management of patients with ABPA 
and AAS [71]. 
The optimal duration of treatment is yet to be determined. 
Topical corticosteroids alone, the mainstay of therapy for allergic 
rhinosinusitis, are not sufficient to bring symptomatic relief. While 
oral antifungals do not seem to have a clear cut benefit, the role 
of topical antifungal agents is still unknown. It was presumed 
that by decreasing the fungal load using antifungal drugs, 
antigenic stimulation would be reduced thereby decreasing the 
inflammatory response. A randomised placebo controlled trial 
with 32 weeks of oral itraconazole in patients with severe asthma 
and fungal sensitisation demonstrated significant improvements 
in quality of life and modest improvements in some of the clinical 
endpoints of asthma and rhinitis [72]. The Cochrane Database 
review [73] on azoles for ABPA inferred that itraconazole, in 
addition to modifying the immunologic activation associated with 
ABPA, improved clinical outcome. However, such studies have 
yet to be replicated in patients with AFS/AAS. The role of allergen 
immunotherapy in AFS too has been investigated [74]. 
CONCLUSION
Allergic Aspergillus sinusitis, a chronic indolent disease, is 
characterised by the presence of ‘allergic mucin’ in the sinonasal 
material obtained for histopathology. This must be sought for in 
all patients with rhinosinusitis with a positive skin allergy test to 
Aspergillus or other fungal antigens. The association of ABPA and 
AAS is not as uncommon as it appears. These entities share similar 
immunopathologic mechanisms, and the mainstay of treatment 
for both these diseases is oral prednisolone. Since asthma and 
sinusitis are two diseases often treated by two different specialties, 
the occurrence of AAS in ABPA and of ABPA in AAS may easily be 
overlooked [8].  Emphasis on early recognition of chest symptoms 
in patients with AAS and nasal symptoms in patients with ABPA 
could increase the diagnosis of contemporaneous involvement, 
and possibly reduce morbidity.
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